在超重和肥胖人群中满足ACR肺癌筛查CT剂量指南
研究纳入2012年12月至2017年12月共1478例基线肺癌筛查CT患者,按BMI分类分析辐射剂量指标。结果显示所有BMI分类和性别均满足ACR剂量要求,本 program 平均CTDIvol和有效剂量低于2017年全国平均水平,肥胖患者剂量也低于全国肥胖患者。
要点
- 在超重和肥胖为主的筛查人群中,CT剂量可满足ACR肺癌筛查剂量指南。
- 男性剂量指标高于女性,相同BMI分类内男女剂量差异有统计学意义(p < 0.001)。
- 本 program 平均CTDIvol 2.45 ± 1.14 mGy、有效剂量1.26 ± 0.59 mSv,低于2017年全国平均3.24 mGy和1.35 mSv。
临床应用与阅片要点
- 可按BMI分类对肺癌筛查CT的辐射剂量进行适当调整。
- 肥胖患者中本 program 平均剂量指标低于全国肥胖患者平均水平。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: Lung cancer screening adoption coincides with a growing obesity epidemic. Maintaining high-quality imaging at low radiation dose is challenging in obesity. We investigate the feasibility of meeting American College of Radiology (ACR) dose guidelines for lung cancer screening in a predominantly overweight and obese population.
MATERIALS AND METHODS: Radiation dose (Volumetric CT dose index [CTDIvol], dose-length product), and body mass index (BMI) were collected for baseline screening CTs December, 2012-December, 2017. Dose metrics were analyzed according to BMI classification (normal <25, overweight 25-29, obese ≥30 kg/m2), using k = 0.014 mSv/mGy*cm. Results were compared to ACR dose guidelines and mean national 2017 Lung Cancer Screening Registry dose metrics. Analysis used Kruskal-Wallis (SPSS, version 24.0.0, IBM corp, Armonk, NY).
RESULTS: Study population comprised 1478 patients (49.2% [727] women: mean BMI 28.1 ± 6.5 kg/m2, 26.9% [397] normal weight, 35.9% [530] overweight, 37.2% [551] obese). ACR dose requirements were met for both genders in all BMI classifications. Dose metrics were higher in men than in women; median effective dose and CTDIvol were 1.39 (0.8-1.58) mSv and 2.78 (1.41-2.80) mGy in men versus 1.16 (0.71-1.43) mSv and 2.70 (1.4-2.78) mGy in women. There were significant differences in dose metrics between men and women in the same BMI classification and between BMI classifications (p < 0.001). Mean dose metrics in our program were considerably lower than 2017 national average- mean CTDIvol and effective dose 2.45 ± 1.14 mGy and 1.26 ± 0.59 mSv versus 3.24 mGy and 1.35 mSv, respectively for our program and nationally. Mean dose metrics were also lower in our obese patients versus obese patients nationally.
CONCLUSION: ACR dose metrics for lung cancer screening were met and can be appropriately tailored in a predominantly overweight and obese population clinical program.
引用
- Peng R, Mardakhaev E, Shmukler A, et al. Meeting ACR Dose Guidelines for CT Lung Cancer Screening in an Overweight and Obese Population. Acad Radiol. 2020. PMID: 32284173. doi:10.1016/j.acra.2020.02.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。